Review of medical management of prostate cancer
10.3760/cma.j.issn.1673-422X.2010.11.020
- VernacularTitle:前列腺癌的内科治疗
- Author:
Rui WANG
- Publication Type:Journal Article
- Keywords:
Prostate Neoplasms;
Drug therapy
- From:
Journal of International Oncology
2010;37(11):865-868
- CountryChina
- Language:Chinese
-
Abstract:
The procedure of treating prostate cancer is as the following: After local prostatectomy or radiotherapy or local palliative therapy, androgen-dependent prostate cancer(ADPC) should be given first-line endocrinal therapy. Almost all patients will be developed from ADPC to hormone independent prostate cancer (HIPC) after 14 ～ 30 months, including androgen-independent prostate cancer(AIPC) and hormone-refractory prostate cancer(HRPC). Second-line endocrinal therapy and chemotherapy should be given, respectively. Antibone metastasis therapy is given when bone metastasis occurred. All medical methods should be used rationally and comprehensively to improve the management of prostate cancer.
